Clinical trial
ET 743 (Yondelis) in Men With Advanced Prostate Cancer
NCT00147212 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00147212 |
|---|---|
| Title | ET 743 (Yondelis) in Men With Advanced Prostate Cancer |
| Official title | A Phase II Study of Three Hour, Weekly Infusion of ET 743 (Yondelis) in Men With Advanced Prostate Cancer |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute PharmaMar Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | ET 743 |
| Enrollment | 50 |
| Start date | Jun 1, 2002 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Sep 7, 2005 |
| Last update posted | Jan 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: